Navigation Links
SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
Date:8/29/2007

ST. LOUIS, Aug. 29 /PRNewswire-FirstCall/ -- SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL), has announced a $4.5 million capacity expansion program at its flagship SAFC Pharma(TM) high-potency API (HPAPI) facility in Madison, Wisconsin. The program, scheduled for commission in early 2008, will add additional cGMP pilot plant and kilo lab capacity and complement the new XRPD (X-ray Powder Diffraction) analytical equipment for advanced solid form testing due to become operational this month.

These developments build upon existing capabilities and expertise in potent compound handling at the Safebridge(R)-certified SAFC Madison facility and add to a $12 million, 38,000 sq. ft. expansion program completed in 2006.

New HPAPI Assets:

In the $4 million expansion, SAFC is adding additional capacity to its custom HPAPI manufacturing by introducing two 400-liter cGMP pilot plant reactors and two 100-liter cGMP portable jacketed reactors into a 1200 sq.ft. dedicated, large-scale kilo lab. The addition will enable larger-scale chromatography for process purification, catering to future business requirements.

For solid-form testing and analysis, SAFC Pharma has installed and qualified a Bruker D8 Advance X-ray Diffractometer in a new dedicated analytical laboratory, providing U.S. customers with on-site cGMP and XRPD analysis of potent compounds. Rapid sample testing at the Madison site combines with data analysis and evaluation performed at SAFC Pharmorphix(TM) facilities in the U.K. Acquired in mid-2006, SAFC Pharmorphix specializes in solid-form research and is completing a multi-phase, $1.2 million expansion program at its labs.

SAFC President, Frank Wicks, comments, "As regulatory requirements align with the increasing complexity of drugs, solid-form testing, analysis and optimization are becoming key elements in the drug development process. Additional and enhanced capabilities at SAFC Pharma's Madison facility mark a timely expansion to the scope and value of our HPAPI offering and are reflective of SAFC's ability to support its customers throughout the drug development cycle."

SAFC Pharma is focused on cGMP manufacturing, process development and contract services for small organic APIs and advanced intermediates, and the development of large molecule biopharmaceuticals.

About SAFC: SAFC(R) is the manufacturing group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four operating segments -- SAFC Pharma(TM), SAFC Supply Solutions(TM), SAFC Biosciences(TM), and SAFC Hitech(TM) -- and had annual sales of nearly $500 million in 2006. SAFC is one of the world's 10 largest fine chemical businesses. For more information about SAFC, please visit http://www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

SAFC(R) is a registered trademark of Sigma-Aldrich Biotechnology L.P. SAFC Pharma(TM), SAFC Supply Solutions(TM), SAFC Biosciences(TM), SAFC Hitech(TM) and Pharmorphix(TM) are trademarks of Sigma-Aldrich Biotechnology L.P. Safebridge(R) is a registered trademark of Safebridge Consultants, Inc.


'/>"/>
SOURCE Sigma-Aldrich Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WARF expands license agreement with Advanced Cell Technology
2. Verizon expands broadband service in Wisconsin
3. Bandwidth provider expands in Milwaukee
4. Wisconsins biodiesel network expands
5. Quad/Graphics expands reach in western states
6. University of South Florida expands GE Healthcare relationship
7. Metavante expands healthcare payments division
8. Fiserv expands services to health plan market
9. Bone Care expands patent protection of core drug offering
10. SBC and AT&T merger expands global reach for Wisconsin businesses
11. Expetec expands IT staff services in Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental challenge ... to full-size tissues, bones, even whole organs to implant in people to treat ... deep into the developing tissue. , Current bioengineering techniques, including 3-D printing, ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
Breaking Biology Technology:
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
Breaking Biology News(10 mins):